New test may predict olaparib success in advanced breast cancer
NCT ID NCT05340413
First seen Mar 16, 2026 · Last updated May 19, 2026 · Updated 9 times
Summary
This study looked at 65 people with advanced HER2-negative breast cancer who have certain gene mutations. Researchers used a test called RAD51-foci to see if it could predict how well the drug olaparib would work. The goal was to find a better way to match patients with the right treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H Clinic de Barcelona
Barcelona, Spain
-
H Vall d Hebron
Barcelona, Spain
-
H. 12 de Octubre
Madrid, Spain
-
H. C. U. Valencia
Valencia, Spain
-
H. San Cecilio
Granada, Spain
Conditions
Explore the condition pages connected to this study.